WARREN, NJ: Makovsky & Company will spearhead a campaign by
pharmaceutical company Celgene to expand its controversial drug
Thalidomide to European and Australian markets.
Once banned in the US, the drug was given limited FDA approval in 1998
as a treatment for leprosy. More recently, however, it has become known
as an experimental treatment for cancer.
However, the drug faces a tough market in Europe, where during the 1950s
and early 1960s, Thalidomide was prescribed to pregnant women for
morning sickness and as a sleep aid.
More than 10,000 'Thalidomide children' were born, often with extreme
Makovksy, Thalidomide's US agency, will manage the international
expansion of the drug through its Australia and London bureaux.
The international offices will report directly to Donna Ramer, MD of
healthcare in Makovsky's New York office.